glucagon-like peptide-1(28-36)amide

suppresses glucose production and oxidative stress in murine hepatocytes

Also Known As:

FIAWLVKGRamide; GLP-1(28-36)amide; GLP1(28-36)amide; Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2; phenylalanyl-isoleucyl-alanyl-tryptophyl-leucyl-valyl-lysyl-glycyl-argininamide

Networked: 4 relevant articles (3 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Peptide Fragments: 373
    - glucagon-like peptide-1(28-36)amide: 4
Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones: 80400
  - Gastrointestinal Hormones: 573
    - Proglucagon: 128
      - Glucagon-Like Peptides: 424
        Glucagon-Like Peptide 1: 6089
        glucagon-like peptide-1(28-36)amide: 4

Experts

1.	Habener, Joel F: 2 articles (08/2011 - 04/2011)
2.	Stanojevic, Violeta: 2 articles (08/2011 - 04/2011)
3.	Tomas, Eva: 2 articles (08/2011 - 04/2011)
4.	Huang, Kun: 1 article (01/2014)
5.	Ji, Kaige: 1 article (01/2014)
6.	Peng, Anlin: 1 article (01/2014)
7.	Yang, Xin: 1 article (01/2014)
8.	Zhou, Bilan: 1 article (01/2014)
9.	Chiang, Yu-Ting Alex: 1 article (12/2013)
10.	Ip, Wilfred: 1 article (12/2013)

Related Diseases

1.	Hyperglycemia 04/11/2011 - "GLP-1(28-36)amide, or a peptide mimetic derived there from, might prove to be a useful treatment for fasting hyperglycemia and metabolic syndrome in type 2 diabetes." 08/08/2011 - "GLP-1(28-36)amide inhibited weight gain, accumulation of liver triglycerides, and improved insulin sensitivity by attenuating the development of fasting hyperglycemia and hyperinsulinemia in mice fed VHFD. "
2.	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/08/2011 - "Therefore, the effects of GLP-1(28-36)amide were examined in diet-induced obese, insulin-resistant mice as a model for the development of human metabolic syndrome. " 08/08/2011 - "These findings suggest utility of GLP-1(28-36)amide, or a peptide mimetic derived there from, for the treatment of insulin resistance and the metabolic syndrome." 04/11/2011 - "GLP-1(28-36)amide, or a peptide mimetic derived there from, might prove to be a useful treatment for fasting hyperglycemia and metabolic syndrome in type 2 diabetes."
3.	Weight Gain 08/08/2011 - "GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice." 01/01/2014 - "GLP-1(28-36)amide has long been regarded as a metabolically inactive byproduct, however, recent findings reveal that GLP-1(28-36)amide plays multiple novel roles in ameliorating hepatic metabolism, protecting β cells, improving glucose disposal and inhibiting weight gain. " 08/08/2011 - "GLP-1(28-36)amide inhibited weight gain, accumulation of liver triglycerides, and improved insulin sensitivity by attenuating the development of fasting hyperglycemia and hyperinsulinemia in mice fed VHFD. "
4.	Insulin Resistance 08/08/2011 - "These findings suggest utility of GLP-1(28-36)amide, or a peptide mimetic derived there from, for the treatment of insulin resistance and the metabolic syndrome." 08/08/2011 - "GLP-1(28-36)amide exerts insulin-like actions selectively in conditions of obesity and insulin resistance. " 08/08/2011 - "GLP-1(28-36)amide inhibited weight gain, accumulation of liver triglycerides, and improved insulin sensitivity by attenuating the development of fasting hyperglycemia and hyperinsulinemia in mice fed VHFD. "
5.	Hyperinsulinism (Hyperinsulinemia) 08/08/2011 - "GLP-1(28-36)amide inhibited weight gain, accumulation of liver triglycerides, and improved insulin sensitivity by attenuating the development of fasting hyperglycemia and hyperinsulinemia in mice fed VHFD. "

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	Triglycerides (Triacylglycerol)
3.	Insulin (Novolin)
4.	Glucose (Dextrose)